Barrow Neurologist Discusses Alzheimer’s Drug Trial Results

marwan sabbagh
Marwan Sabbagh, MD

A study published in the New England Journal of Medicine found that an experimental Alzheimer’s drug, known as lecanemab, moderately slowed the progression of the disease. However, the researchers say longer clinical trials are needed to evaluate the safety of this amyloid-targeting drug.

Marwan Sabbagh, MD, a neurologist in the Alzheimer’s and Memory Disorders Program at Barrow Neurological Institute and a co-author on the study, discussed these safety concerns at the 15th Clinical Trials on Alzheimer’s Disease conference in San Francisco, California. He has been quoted by several news outlets.